… I study of dual T-cell checkpoint inhibition with ipilimumab and nivolumab in patients with
advanced stage III or IV melanoma [84]. Patients were treated with both ipilimumab (1 or 3 mg/…

… insurance support, the treatment of lung cancer has entered a … -1/PD-L1 antibodies treatment,
both when used alone and in … immune checkpoint inhibitors used for treating lung cancer. …

… Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer … and
Drug Administration approval for the treatment of a wide array of cancer types, demonstrating …

… one of the most immunogenic human cancers, an improvement in … treatments. In this chapter
we discuss the discovery of immune checkpoints, the clinical application of their inhibitors …

… , head and neck cancers and non-small lung cancer. The US FDA … checkpoint inhibitors
(ICIs) such as PD-1 inhibitors (Nivolumab, Pembrolizumab, and Cemiplimab), PDL-1 inhibitors (…

… identify those cancer patients who will benefit from treatment by checkpoint inhibition. The
current overview summarizes current knowledge on immune checkpoint inhibitor treatment in …

… of immune checkpoint inhibitors with other cancer treatment modalities are … checkpoint
inhibitors as a new class of cancer therapeutics is changing the paradigm of cancer treatment…

… known as immune checkpoints. This review focuses on the immune checkpoint inhibitors,
a … and differences among the three immune checkpoint inhibitors approved by the US Food …

… tors have received FDA approval for the treatment of various cancer types (Table 1) [4]. …
mune checkpoint inhibitors (ICIs) approved to be used for the treatment of several types of cancer…

… development of checkpoint inhibitors. This shifted the focus from developing therapies that
targeted activation of the host immune system against cancer to checkpoint inhibitors, which …